Review anchor
cGMP-dependent 3',5'-cyclic phosphodiesterase
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
Evidence Snapshot
cGMP-dependent 3',5'-cyclic phosphodiesterase
CHEMBL4650
SINGLE PROTEIN
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats cGMP-dependent 3',5'-cyclic phosphodiesterase as ChEMBL target CHEMBL4650, mapped to UniProt Q01062. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4650
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q01062
cGMP-dependent 3',5'-cyclic phosphodiesterase
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why cGMP-dependent 3',5'-cyclic phosphodiesterase matters
cGMP-dependent 3',5'-cyclic phosphodiesterase is reviewed as cGMP-dependent 3',5'-cyclic phosphodiesterase (UniProt Q01062); the current evidence base includes 0 approved drugs, 51 compounds, and 17 assays, with lead potency reaching pChEMBL 8.6.
Protein context
cGMP-dependent 3',5'-cyclic phosphodiesterase
cGMP-dependent 3',5'-cyclic phosphodiesterase Sequence length is 928 aa.
Review this target as cGMP-dependent 3',5'-cyclic phosphodiesterase, mapped to UniProt Q01062. Sequence length is 928 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q01062
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 51 compounds, and 17 assays for this target. The dominant activity type is IC50. CHEMBL4098282 is the current potency anchor at pChEMBL 8.6.
Use CHEMBL4098282 as the tractability anchor when discussing potency (pChEMBL 8.6).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 8.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why cGMP-dependent 3',5'-cyclic phosphodiesterase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q01062, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
51
Total Compounds
17
Total Assays
0
Approved Drugs
IC50: 39.0, KI: 1.0, EC50: 1.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4098282
|
8.6 | Kd | — |
|
|
No preferred name
CHEMBL3092562
|
8.4 | Ki | — |
|
|
No preferred name
CHEMBL4074744
|
6.2 | EC50 | — |
|
|
No preferred name
CHEMBL100779
|
5.8 | IC50 | — |
|
|
No preferred name
CHEMBL118462
|
4.8 | IC50 | — |
Source Header